
    
        <!DOCTYPE html>
        <html lang="hu-HU" data-website-id="1" data-oe-company-name="HBS Medical">
            
<!-- Mirrored from hbs.hu/slides/slide/intravesical-administration-of-combined-hyaluronic-acid-ha-and-chondroitin-sulfate-cs-for-the-treatment-of-female-recurrent-urinary-tract-infections-2016-bmjopen-2015-009669-30 by HTTrack Website Copier/3.x [XR&CO'2014], Mon, 31 May 2021 16:04:06 GMT -->
<!-- Added by HTTrack --><meta http-equiv="content-type" content="text/html;charset=utf-8" /><!-- /Added by HTTrack -->
<head>
                <meta charset="utf-8"/>
                <meta http-equiv="X-UA-Compatible" content="IE=edge,chrome=1"/>
                <meta name="viewport" content="width=device-width, initial-scale=1, user-scalable=no"/>

                <title>Intravesical administration of combined hyaluronic acid (HA) and chondroitin sulfate (CS) for the treatment of female recurrent urinary tract infections 2016 bmjopen-2015-009669 | HBS</title>
                <link type="image/x-icon" rel="shortcut icon" href="../../web/image/website/1/favicon/index.html"/>

                <script type="text/javascript">
                    var odoo = {
                        csrf_token: "f2e9a41588799d043a772b21ddc3189150ea199fo",
                    };
                </script>

                
            <meta name="generator" content="Odoo"/>

            
            
            
            
            
            
                
                
                
                    
                        <meta property="og:type" content="website"/>
                    
                        <meta property="og:title" content="Intravesical administration of combined hyaluronic acid (HA) and chondroitin sulfate (CS) for the treatment of female recurrent urinary tract infections 2016 bmjopen-2015-009669"/>
                    
                        <meta property="og:site_name" content="HBS Medical"/>
                    
                        <meta property="og:url" content="https://hbs.hu/slides/slide/intravesical-administration-of-combined-hyaluronic-acid-ha-and-chondroitin-sulfate-cs-for-the-treatment-of-female-recurrent-urinary-tract-infections-2016-bmjopen-2015-009669-30"/>
                    
                        <meta property="og:image" content="https://hbs.hu/web/image/slide.slide/30/image_thumb"/>
                    
                        <meta property="og:description"/>
                    
                
                
                
                    
                        <meta name="twitter:card" content="summary_large_image"/>
                    
                        <meta name="twitter:title" content="Intravesical administration of combined hyaluronic acid (HA) and chondroitin sulfate (CS) for the treatment of female recurrent urinary tract infections 2016 bmjopen-2015-009669"/>
                    
                        <meta name="twitter:image" content="https://hbs.hu/web/image/slide.slide/30/image_thumb"/>
                    
                        <meta name="twitter:description"/>
                    
                
            

            
            
                
                    <link rel="alternate" hreflang="hu" href="intravesical-administration-of-combined-hyaluronic-acid-ha-and-chondroitin-sulfate-cs-for-the-treatment-of-female-recurrent-urinary-tract-infections-2016-bmjopen-2015-009669-30.html"/>
                
            

            <script type="text/javascript">
                odoo.session_info = {
                    is_admin: false,
                    is_system: false,
                    is_frontend: true,
                    translationURL: '/website/translations',
                    is_website_user: true,
                    user_id: 4
                };
                
            </script>

            <link type="text/css" rel="stylesheet" href="../../web/content/521-3ab7b2c/1/web.assets_common.0.css"/>
            <link type="text/css" rel="stylesheet" href="../../web/content/599-e81acc7/1/web.assets_frontend.0.css"/>
            <link type="text/css" rel="stylesheet" href="../../web/content/600-e81acc7/1/web.assets_frontend.1.css"/>
            
            
            

            <script type="text/javascript" src="../../web/content/524-3ab7b2c/1/web.assets_common.js"></script>
            <script type="text/javascript" src="../../web/content/603-e81acc7/1/web.assets_frontend.js"></script>
            
            
            
        
            </head>
            <body>
                
            
        
            
        
        
            
                
                    
                
                
            
        
        
    
    

            
            
        
    
            
          
        <link rel="stylesheet" type="text/css" href="../../sh_cookie_notice/static/src/css/cookieconsent.min.css"/>
        <script type="text/javascript" src="../../sh_cookie_notice/static/src/js/cookieconsent.min.js"></script>
        

	
	<script type="text/javascript"> 

	 window.addEventListener("load", function(){
 
	var sh_msg = String("Az HBS weboldala sütiket használ a weboldal működtetése, használatának megkönnyítése, a weboldalon végzett tevékenység nyomon követése és releváns ajánlatok megjelenítése érdekében.");
	var sh_esc_msg = encodeURIComponent(sh_msg);
	sh_esc_msg = decodeURIComponent(sh_esc_msg); 
	
  	window.cookieconsent.initialise({
	  "palette": {
	    "popup": {
	      "background": "#000" 
	    },
	    "button": {
	      "background": "#f1d600"
	    }
	  },
	  
	  	  "position": "top",
	  
	
	  
	  "content": {
	    "message": sh_esc_msg,
	    "dismiss": "Elfogadom",
	    "allow": "allow",
	    "link": "Adatvédelmi tájékoztató",
	    "href": "/adatkezelesi-tajekoztato"
	  }
	})});
    </script>
 
   
    <div id="wrapwrap" class="   ">
                <header class=" o_affix_enabled">
                    <nav class="navbar navbar-expand-md navbar-light bg-light">
                        <div class="container">
                            <a href="../../index.html" class="navbar-brand logo">
            <span role="img" aria-label="Logo of HBS Medical" title="HBS Medical"><img src="../../web/image/res.company/1/logo66cf.png?unique=866a03a" class="img img-fluid"/></span>
        </a>
    <button type="button" class="navbar-toggler" data-toggle="collapse" data-target="#top_menu_collapse">
                                <span class="navbar-toggler-icon"></span>
                            </button>
                            <div class="collapse navbar-collapse" id="top_menu_collapse">
                                <ul class="nav navbar-nav ml-auto text-right o_menu_loading" id="top_menu">
                                    
        
            
    
    <li class="nav-item">
        <a role="menuitem" href="../../index.html" class="nav-link ">
            <span>HBS Medical</span>
        </a>
    </li>
    

        
            
    
    <li class="nav-item">
        <a role="menuitem" href="../../../covid-19.hbs.hu/index.html" class="nav-link " target="_blank">
            <span>COVID-19</span>
        </a>
    </li>
    

        
            
    
    <li class="nav-item">
        <a role="menuitem" href="../../blog/hirek-esemenyek-1.html" class="nav-link ">
            <span>Hírek</span>
        </a>
    </li>
    

        
            
    
    <li class="nav-item">
        <a role="menuitem" href="../../aboutus.html" class="nav-link ">
            <span>Kapcsolat</span>
        </a>
    </li>
    

        
    
                                    
                                </ul>
                            </div>
                        </div>
                    </nav>
                </header>
                <main>
                    
        
        <div class="container mt16">
            <div class="row">
                <div class="col-xl-8 col-lg-8 col-md-12 col-12">
                    

                    <div>
                            
                        <div class="embed-responsive embed-responsive-4by3 embed-responsive-item mb8">
                            <iframe src="../embed/302679.html?page=1" class="o_wslides_iframe_viewer" allowFullScreen="true" height="315" width="420" frameborder="0"></iframe>
                        </div>
                        
                        <div class="row">
                            <h4 class="col-lg-6">Intravesical administration of combined hyaluronic acid (HA) and chondroitin sulfate (CS) for the treatment of female recurrent urinary tract infections 2016 bmjopen-2015-009669</h4>
                            <div class="col-lg-6">
                                <div clas="row">
                                    
                                </div>
                            </div>
                        </div>
                        <div class="row">
                            <div class="col-md-8 col-12">
                                <div class="float-left">
                                    <a href="../nyilvanos-anyagok-1.html" title="Channel Nyilvános anyagok" aria-label="Channel Nyilvános anyagok">
                                        <i class="fa fa-circle-o fa-5x" style="color: #875A7B;font-weight: bold;"></i>
                                    </a>
                                </div>
                                <div style="margin-left: 80px">
                                    <p>
                                        <a href="../nyilvanos-anyagok-1.html">Nyilvános anyagok</a>
                                        
                                            <span> / </span>
                                            <a href="../nyilvanos-anyagok-1/category/szakirodalmi-cikkek-3.html">Szakirodalmi cikkek</a>
                                        
                                    </p>
                                    <div>
                                        
        <div class="input-group js_follow" data-id="1" data-object="slide.channel" data-follow="off">
            <input type="email" name="email" class="js_follow_email form-control" placeholder="emailje..."/>
            <div class="input-group-append">
                <button href="#" class="btn btn-secondary js_unfollow_btn">Leiratkozás</button>
                <button href="#" class="btn btn-primary js_follow_btn">Feliratkozás</button>
            </div>
        </div>
    
                                    </div>
                                </div>
                            </div>
                            <div class="col-md-4 d-none d-md-block">
                                <div class="text-right">
                                    <b class="h3 text-muted">1220</b> <span class="text-muted small">views</span>
                                </div>
                                
                                <div class="progress mb0" style="height: 2px;">
                                    <div class="progress-bar" role="progressbar" aria-valuenow="0" aria-valuemin="0" aria-valuemax="100" style="width: 0%;">
                                        <span class="sr-only">0 Likes</span>
                                    </div>
                                </div>
                                <div class="text-muted mt4">
                                    <div class="float-right mb16 text-right">
                                        <span class="oe_slide_js_like" data-href="/slides/slide/like" tabindex="0" data-toggle="popover" data-user-id="4" data-public-user="True" data-slide-id="30">
                                            <i class="fa fa-thumbs-up fa-1x" role="img" aria-label="Likes" title="Likes"></i>
                                            0
                                        </span>
                                        <span class="oe_slide_js_unlike" data-href="/slides/slide/dislike" tabindex="0" data-toggle="popover" data-user-id="4" data-public-user="True" data-slide-id="30">
                                            <i class="fa fa-thumbs-down fa-1x" role="img" aria-label="Dislikes" title="Dislikes"></i>
                                            0
                                        </span>
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="mt8 mb32">
                            <ul class="nav nav-tabs" role="tablist">
                                <li class="nav-item">
                                    <a href="#about" aria-controls="about" role="tab" data-toggle="tab" class="nav-link active">
                                        <i class="fa fa-home"></i> About
                                    </a>
                                </li>
                                <li class="nav-item">
                                    <a href="#share" aria-controls="share" class="nav-link" role="tab" data-toggle="tab">
                                        <i class="fa fa-share-alt"></i> Share
                                    </a>
                                </li>
                                <li class="nav-item">
                                    <a href="#discuss" aria-controls="discuss" role="tab" data-toggle="tab" class="nav-link">
                                        <i class="fa fa-comments-o"></i> Comments
                                    </a>
                                </li>
                                <li class="nav-item">
                                    <a href="#transcript" aria-controls="transcript" class="nav-link" role="tab" data-toggle="tab">
                                        <i class="fa fa-align-justify"></i> Transcript
                                    </a>
                                </li>
                                <li class="nav-item">
                                    <a href="#statistic" aria-controls="statistic" class="nav-link" role="tab" data-toggle="tab">
                                        <i class="fa fa-bar-chart"></i> Statistics
                                    </a>
                                </li>
                            </ul>
                            <div class="tab-content" style="padding: 20px 5px 5px 5px; word-wrap: break-word;">
                                <div role="tabpanel" id="about" class="tab-pane fade active in">
                                    
                                </div>
                                <div role="tabpanel" class="tab-pane fade" id="share">
                                    
    <h4 class="mt0">Share on Social Networks</h4>
    
    <div>
        <a class="o_slides_social_share" social-key="facebook" aria-label="Share on Facebook" title="Share on Facebook" href="https://www.facebook.com/sharer/sharer.php?u=https://hbs.hu/r/6a7"><i class="fa fa-facebook-square fa-2x"></i></a>
        <a class="o_slides_social_share" social-key="twitter" aria-label="Share on Twitter" title="Share on Twitter" href="https://twitter.com/intent/tweet?text=Intravesical%20administration%20of%20combined%20hyaluronic%20acid%20(HA)%20and%20chondroitin%20sulfate%20(CS)%20for%20the%20treatment%20of%20female%20recurrent%20urinary%20tract%20infections%202016%20bmjopen-2015-009669&amp;url=https://hbs.hu/r/6a7"><i class="fa fa-twitter fa-2x"></i></a>
        <a social-key="linkedin" class="o_slides_social_share" aria-label="Share on LinkedIn" title="Share on LinkedIn" href="https://www.linkedin.com/shareArticle?mini=true&amp;url=https://hbs.hu/r/6a7&amp;title=Intravesical%20administration%20of%20combined%20hyaluronic%20acid%20(HA)%20and%20chondroitin%20sulfate%20(CS)%20for%20the%20treatment%20of%20female%20recurrent%20urinary%20tract%20infections%202016%20bmjopen-2015-009669&amp;"><i class="fa fa-linkedin fa-2x"></i></a>
        <a class="o_slides_social_share" social-key="gplus" aria-label="Share on Google Plus" title="Share on Google Plus" href="https://plus.google.com/share?url=https://hbs.hu/r/6a7"><i class="fa fa-google-plus-square fa-2x"></i></a>
    </div>

    <h4 class="mt-3">Share Link</h4>
    <input type="text" class="form-control" readonly="readonly" onClick="this.select();" value="intravesical-administration-of-combined-hyaluronic-acid-ha-and-chondroitin-sulfate-cs-for-the-treatment-of-female-recurrent-urinary-tract-infections-2016-bmjopen-2015-009669-30.html"/>
    <span class="form-text">Use permanent link to share in social media</span>

                                    
    <h4 class="mt-3">Share with a friend</h4>
    
    
        <p>Please <a href="../../web/login.html?redirect=https://hbs.hu/slides/slide/intravesical-administration-of-combined-hyaluronic-acid-ha-and-chondroitin-sulfate-cs-for-the-treatment-of-female-recurrent-urinary-tract-infections-2016-bmjopen-2015-009669-30"> login </a> to send this document by email!</p>
    

                                    
                                        
    <div class="oe_slide_js_embed_code_widget">
        <h4 class="mt0">Embed in your website</h4>
        <div class="form-group">
            <textarea class="form-control slide_embed_code" readonly="readonly" onClick="this.select();">&lt;iframe src=&quot;https://hbs.hu/slides/embed/30?page=1&quot; class=&quot;o_wslides_iframe_viewer&quot; allowFullScreen=&quot;true&quot; height=&quot;315&quot; width=&quot;420&quot; frameborder=&quot;0&quot;&gt;&lt;/iframe&gt;</textarea>
        </div>
        <div class="form-group">
            <div class="form-text col-xl-3 col-lg-3 col-md-6 col-6">Select page to start with</div>
            <div class="input-group col-xl-3 col-lg-3 col-md-6 col-6">
                <input type="number" value="1" class="form-control"/>
            </div>
        </div>
    </div>

                                    
                                </div>
                                
                                <div role="tabpanel" id="discuss" class="tab-pane fade">
                                    
        <div id="discussion" class="d-print-none o_portal_chatter o_not_editable p-0" data-res_model="slide.slide" data-res_id="30" data-pager_step="10" data-allow_composer="1">
        </div>
    
                                </div>
                                <div role="tabpanel" class="tab-pane fade oe_slides_transcript" id="transcript">
                                    
                                        
                                            <p>1. Intravesical administration of combined hyaluronic acid (HA) and chondroitin sulfate (CS) for the treatment of female recurrent urinary tract infections: a European multicentre nested case – control study Oriana Ciani, 1,2 Erik Arendsen, 3 Martin Romancik, 4 Richard Lunik, 5 Elisabetta Costantini, 6 Manuel Di Biase, 6 Giuseppe Morgia, 7 Eugenia Fragalà, 7 Tomaskin Roman, 8 Marian Bernat, 9 Giorgio Guazzoni, 10 Rosanna Tarricone, 1,11 Massimo Lazzeri 10 To cite: Ciani O, Arendsen E, Romancik M, etal . Intravesical administration of combined hyaluronic acid (HA) and chondroitin sulfate (CS) for the treatment of female recurrent urinary tract infections: a European multicentre nested case – control study. BMJ Open 2016; 6 :e009669. doi:10.1136/bmjopen-2015- 009669 ▸ Prepublication history and additional material is available. To view please visit the journal (http://dx.doi.org/ 10.1136/bmjopen-2015- 009669). Received 10 August 2015 Revised 20 January 2016 Accepted 1 March 2016 For numbered affiliations see end of article. Correspondence to Dr Oriana Ciani; <a href="../../cdn-cgi/l/email-protection.html" class="__cf_email__" data-cfemail="c0afb2a9a1aea1eea3a9a1aea980b5aea9a2afa3a3afaea9eea9b4">[email&#160;protected]</a> ABSTRACT Objectives: To compare the clinical effectiveness of the intravesical administration of combined hyaluronic acid and chondroitin sulfate (HA+CS) versus current standard management in adult women with recurrent urinary tract infections (RUTIs). Setting: A European Union-based multicentre, retrospective nested case – control study. Participants: 276 adult women treated for RUTIs starting from 2009 to 2013. Interventions: Patients treated with either intravesical administration of HA+CS or standard of care (antimicrobial/immunoactive prophylaxis/probiotics/ cranberry). Primary and secondary outcome measures: The primary outcome was occurrence of bacteriologically confirmed recurrence within 12 months. Secondary outcomes were time to recurrence, total number of recurrences, health-related quality of life and healthcare resource consumption. Crude and adjusted results for unbalanced characteristics are presented. Results: 181 patients treated with HA+CS and 95 patients treated with standard of care from 7 centres were included. The crude and adjusted ORs (95% CI) for the primary end point were 0.77 (0.46 to 1.28) and 0.51 (0.27 to 0.96), respectively. However, no evidence of improvement in terms of total number of recurrences (incidence rate ratio (95% CI), 0.99 (0.69 to 1.43)) or time to first recurrence was seen (HR (95% CI), 0.99 (0.61 to 1.61)). The benefit of intravesical HA+CS therapy improves when the number of instillations is ≥ 5. Conclusions: Our results show that bladder instillations of combined HA+CS reduce the risk of bacteriologically confirmed recurrences compared with the current standard management of RUTIs. Total incidence rates and hazard rates were instead non- significantly different between the 2 groups after adjusting for unbalanced factors. In contrast to what happens with antibiotic prophylaxis, the effectiveness of the HA+CS reinstatement therapy improves over time. Trial registration number: NCT02016118. BACKGROUND Urinary tract infection (UTI) is a major healthcare concern in women with an annual incidence of 30 per 1000. 1 Nearly 33% of women will have had at least one UTI episode, with characteristics of acute cystitis, requiring antimicrobial therapy by the age of 24 years and as many as 60% of women reporting having had a UTI in their lifetime. 23 UTIs have a propensity to recur; 45 evi- dence shows that between 24% and 50% of Strengths and limitations of this study ▪ These real-world data show that bladder instilla- tions of combined hyaluronic acid and chondro- itin   sulfate   may   reduce   the   risk   of bacteriologically confirmed urinary tract infec- tions versus current standard management. ▪ However, if the recurrence occurs, there is no evidence of benefit in terms of total number or time to first recurrence. ▪ The number of instillations seems to be an important  marker  of  success  for  this  non- antimicrobial therapy. ▪ Owing to the retrospective observational design, these findings need confirmation from prospect- ive and preferably randomised studies. Ciani O, etal . BMJOpen 2016; 6 :e009669. doi:10.1136/bmjopen-2015-009669 1 Open Access Research </p>
                                        
                                            <p>6. the fi ndings. While waiting for de fi nitive RCT evidence clarifying the comparative effectiveness pro fi le of this therapy in support of its adoption, our observational study design provides useful information around its effectiveness in real-world practice. In this respect, our study involved seven centres across three European countries and 276 patients, thus provid- ing  important  additional  evidence  with  respect  to current treatment options for RUTIs. Furthermore, the non-experimental  observational  design  allows  for  a closer representation of the routine clinical practice of the use of the HA+CS reinstatement therapy as com- pared with standard of care in place at high volume uni- versity hospitals, that is on purpose de fi ned as very broad given the variety of recommended strategies 17 and general scarce adherence to clinical guidelines. 32 On the other hand, the retrospective design limited the availability of data to that previously collected at the centres. Contacting patients ex-post to gather additional data was not applicable (eg, as in the case of HRQoL assessment) or not helpful, given the potential signi fi cant recall bias introduced by delayed reporting. The issue of missing data was dealt with by assuming that they were missing at random (ie, given the observed data, data are missing independently of unobserved data, ie, missing data do not depend on the level of their outcome) and applying pairwise deletion. In this regard, we performed two additional analyses, fi rst by restricting the primary analyses to all-complete-cases (ie, no missing values in outcomes and adjusting variables) and providing similar results to  those  presented  here  (data  not  shown). Second, for all outcomes and adjusting variables, we tested through Fisher ’ s exact test whether proportions of missing  values  was  different  between  HA+CS  and Standard of Care groups. No signi fi cant difference was observed with the exception of the resource consumption where the number of missing values was higher in the HA+CS group. Data on uropathogens and AMR within the groups were unfortunately not available from this database, although we know that the most commonly prescribed antibiotics were cipro fl oxacin (13.2% of all prescriptions), cefurox- ime (6.9%), fosfomycin (6.9%), nitrofurantoin (6.4%) and E. coli bacterial extract (OM-89, 4.8%). HRQoL assessment in routine practice is still uncom- mon, as indicated by the signi fi cant proportion of missing information (up to 73% in the control group) on this outcome. However, our fi ndings are in line with previous reports showing that the GAG replacement treatment in women with RUTIs had a positive impact on patients ’ quality of life, reducing the symptoms and improving the maximum cystometric capacity. 29 30 RUTIs in women are a common condition, associated with signi fi cant morbidity and burden for the whole society. In a study of 684 women aged 18 – 70 years with UTI, participants reported an average of 3.83 symptom days, 2.89 restricted-activity days, and 3.13 days during which they were unwell. 33 In another study, patients reported 1.2 days on which they were not able to attend classes or work, and 0.4 days in bed. 34 New effective pre- vention  strategies  are  needed;  in  particular,  non- antimicrobial approaches would be desirable for several reasons. First of all, a prolonged antibiotic use as a prophylactic approach to RUTI increases the risk of side effects,  including  vaginal  and  oral  candidiasis,  and gastrointestinal  symptoms. 10 This,  in  turn,  lowers patients ’ compliance and therefore the effectiveness of the treatment. 35 However, the most worrying effect of the antibiotic use (and misuse) is the exacerbation of AMR. 36 Recently, a UK commissioned report on health and macroeconomic consequences of AMR estimated 10 million extra deaths a year and costs up to € 90 trillion for the global economy by 2050 if this problem is not tackled properly. 37 Although this fi rst report might not be as scienti fi cally rigorous or informed by evidence as possible, 38 it brought renewed interest in the worldwide AMR crisis. The war against the spread of drug-resistant microbes is attracting considerable attention as well as investment from all major governments and research organisations in the EU and beyond. 39  40 The way forward outlined by all of these major research initiatives includes establishing appropriate funding and rewards to subsidise access to and development of new antibiotic agents, preservation of existing drugs antimicrobial activ- ity through prescription tailored to diagnosis, prioritisa- tion and controlled access, and identi fi cation of novel approaches and therapies for microbial diseases. The case of GAG reinstatement therapy is a good example of an innovative approach to prevent and manage bacterial urinary infections, a medical device intervention as opposed to a drug. In contrast to anti- biotic therapy, which aims at eradicating pathogens, treat- ment with HA+CS targets bacterial adherence to the bladder mucosa by physically recovering a damaged GAG layer that facilitates bacterial adherence and, therefore, RUTIs. Although patients who bene fi t from the treat- ment in the fi rst place might decide to undertake a higher number of instillations compared with patients who do not bene fi t immediately, the different mechan- ism of action could explain the apparent reduction in the incidence of UTIs in the group treated with HA+CS instil- lations compared with standard care when considering later time intervals ( table 3 ). While antibiotics are imme- diately effective, although subject and conducive to resist- ance, GAG layer administration is progressively restoring the epithelium that will protect women from future uro- pathogen infections. On the other hand, catheterisation- induced UTIs might represent an unintended conse- quence of this procedure. Previous reports 29 30 have high- lighted good tolerability and safety of the intervention that must be performed under sterile conditions by nurses trained in the procedure. As regards the economic pro fi le of the two alternative approaches, it has been reported that the cost of HA+CS could be even fi ve times higher than the cost for a 6-month antibiotic prophylaxis. However,  this  consideration  corresponds  to  a  very 6 Ciani O, etal . BMJOpen 2016; 6 :e009669. doi:10.1136/bmjopen-2015-009669 Open Access </p>
                                        
                                            <p>3. prophylaxis (continuous or postcoital), or immunoactive prophylaxis or prophylaxis with probiotics or prophylaxis with cranberry, or a combination of these, 17 as recom- mended by the European Association of Urology. Study outcomes The primary outcome for this study was the occurrence of objective UTI recurrence, de fi ned as the occurrence of at least one bacteriologically con fi rmed UTI within 12 months  after  treatment  initiation  for  RUTIs. According  to  current  clinical  guidelines,  in  non- pregnant women, urine culture is recommended in symptomatic patients only. Information about clinically con fi rmed recurrences was also sought, although they are not reported in this manuscript as they are assumed to be less objective than the bacteriologically con fi rmed ones. Patients who developed a UTI while on the HA+CS instillation protocol were treated according to clinical guidelines with antibiotics but could continue the instillations afterwards. After the fi rst bacteriologic- ally con fi rmed recurrence, the time to fi rst recurrence was recorded, as well as the number of additional UTIs. The secondary outcome measures were the time to recur- rence (de fi ned as the time from the start of the treatment until the occurrence of the fi rst objective recurrence); the total number of recurrences; HRQoL as assessed through the Short Form 36 (SF-36) 23 or Euro QoL 5D (EQ-5D) 24 questionnaires. Dutch, 25 Italian 26 and UK 27 tariffs were used to estimate utility values from the EQ-5D questionnaires in the Netherlands, Italy and Slovakia, respectively. Information about healthcare resource con- sumption was also collected. A cost analysis was planned and will be the subject of a future publication. Data collection General patient demographic characteristics, diagnosis and treatment information were collected on the basis of a prede fi ned form designed on the input obtained from collaborating centres during a workshop held in July 2013. An intuitive electronic system was implemen- ted (Advice Pharma Ltd) to record and store data on a secure remote server provider. Statistical analyses Continuous baseline characteristics are presented as the median and IQR or mean and SD, as appropriate. For proportions,  absolute  and  relative  frequencies  are reported. The Wilcoxon-Mann-Whitney test or Student t test was used for continuous and ordinal variables base- line differences, whereas the χ 2 test was used for propor- tions. In our primary analyses, we applied logistic, Poisson and Cox regression for objective recurrence, number of recurrences and time to recurrence, respect- ively. Results were presented as crude and adjusted OR, incidence rate ratio (IRR) and HR, respectively, with their 95% CIs. Adjusting variables were age, body mass index (BMI), employment and menopause status, post- coital infections, dyspareunia, Female Sexual Function Index (FSFI) and severity of RUTI. A prespeci fi ed sensi- tivity analysis was conducted to investigate the impact of adherence to HA+CS treatment on clinical outcomes considering patients who had ≥ 5 instillations. Pairwise deletion was used to deal with missing data. All signi fi - cance tests were two-tailed at the 0.05 signi fi cance level. All  the  analyses  were  conducted  using  Stata  SE StataCorp LP 11. RESULTS Overall,  276  patients  treated  for  RUTIs  at  seven European centres from January 2009 up to December 2013 were included in the analyses. Of these, 181 women were treated with HA+CS intravesical administra- tion and 95 women received standard management of RUTIs. The numerical imbalance was probably due to the participating organisations being tertiary referral centres for patients who are not satis fi ed with standard management of RUTIs. A fl ow diagram reporting the number of patients at each stage of the study is shown in fi gure 1 . The baseline sociodemographic and clinical characteristics of patients are reported in table 1 . Given the non-experimental nature of the study, the distribu- tion of several characteristics was not homogeneous between the two groups; in particular, women treated with HA+CS were older, with a higher BMI and probabil- ity of dyspareunia. Primary analyses In the HA+CS group, 55.7% of patients showed bacterio- logically con fi rmed recurrences, whereas 62.1% had such recurrence in the standard of care group (p=0.313). However, the adjusted OR (95% CI) for developing a bac- teriologically con fi rmed recurrence within 12 months was 0.51 (0.27 to 0.96), meaning that, other characteristics being equal, there is a 49% reduced risk of developing a recurrence in patients treated with HA+CS compared with standard care ( table 2 ). When the number of re- currences is considered, in the HA+CS group there were 121 bacteriologically con fi rmed recurrences in 61.5 Figure 1 Flow diagram describing numbers of individuals at each stage of study. HA+CS, hyaluronic acid and chondroitin sulfate. Ciani O, etal . BMJOpen 2016; 6 :e009669. doi:10.1136/bmjopen-2015-009669 3 Open Access </p>
                                        
                                            <p>2. initial episodes are followed by a second infection within 6 months. 6 – 9 A widely accepted de fi nition of recurrent UTIs  (RUTIs)  is two  or  more  UTI  episodes  over 6 months, or three or more episodes over 12 months. 10 On a population scale, the high incidence and preva- lence of RUTIs results in considerable healthcare costs; at the individual level, the impact of this condition on health-related quality of life (HRQoL) is not negli- gible. 11 – 13 The pathogenesis of RUTI involves colonisation of the vagina with  uropathogenic  bacteria and  subsequent migration per urethra to the bladder. About 68 – 77% of recurrences caused by Escherichia coli involve strains gen- etically indistinguishable from those that caused previ- ous infections. 14 The diagnosis is often made on clinical presentation with local genitourinary symptoms of dysuria, frequency, and  urgency  or  hesitancy  appearing  suddenly. 14 However, urine culture is useful in women presenting with RUTI to con fi rm the diagnosis, direct antimicrobial therapy  and  exclude  infection  from  an  overactive bladder or interstitial cystitis. 15 Evidence-based clinical practice guidelines recommend empiric initial therapy for acute  management  or  continuous  antimicrobial therapy or self-initiated therapy and prophylaxis, either antimicrobial or non-antimicrobial based. 16 17 The choice of speci fi c strategy for care depends on the number of recurrences experienced per year, the patient ’ s preferences and careful review of modi fi able risk factors. 14 18 As the second most common reason for prescribing antibiotics (following otitis media), there is currently increasing concern about empiric use of these agents due to increased antimicrobial resistance (AMR). Antibiotic use selects for resistant pathogens: a major risk factor for an antibioticresistant UTI is prior anti- biotic use. 5 In an international survey investigating the prevalence and susceptibility of pathogens causing cyst- itis, 10.3% of E.  coli isolates were resistant to at least three different classes of antimicrobial agents, including ampicillin   (48.3%),   trimethoprim/sulfamethoxazole (29.4%) and nalidixic acid (18.6%). 19 Non-antimicrobial prevention strategies have become popular in the age of increasing antimicrobial use and resistance.  However,  no  probiotic  agent  has  been approved for therapeutic use and the potential bene fi t of cranberry in terms of product type (solid vs liquid), dosing and optimal patient population remains to be elucidated. 14 18 A new therapy based on the reinstate- ment of the glycosaminoglycan (GAG) bladder epithe- lium has recently been proposed for the treatment of RUTIs. 20 This GAG layer consists of non-sulfated, for example,  hyaluronic  acid  (HA),  and  sulfated,  for example,  heparan  sulfate  and  heparin,  chondroitin sulfate  (CS),  dermatan  sulfate  and  keratan  sulfate, GAGs. Limited evidence has shown the preventive activ- ity of intravesical GAG substation therapy (with HA alone or with HA+CS) on recurrence of infections in patients  with  recurrent  bacterial  cystitis. 21 However, large-scale studies are needed to underline the bene fi t of this therapy. 22 Therefore, we decided to perform a European retro- spective multicentre study to compare the clinical effect- iveness of the intravesical administration of combined HA+CS (ialuril, IBSA Institut Biochimique SA) versus current  standard  management  of  RUTIs  in  adult women. METHODS Study design This was a European Union (EU) based multicentre, retrospective nested case – control comparison of individ- ual  patient  data  collected  from  electronic  medical records and/or administrative databases available at the participating institutions. Centres using the intravesical administration of combined HA+CS, in the countries where ialuril was already registered and on the market (ialuril received a CE mark for this indication in 2009), were identi fi ed and invited to take part in the study. Study population All patients treated with either HA+CS or standard of care at the participating centres, high volume organisa- tions with speci fi c expertise in the treatment of UTIs, starting from 2009, were included if they were women, aged 18 – 75 years, diagnosed with RUTIs, de fi ned as at least three episodes of uncomplicated UTIs accompan- ied by clinical symptoms and documented by urine culture with the isolation of &gt;10 3 CFU/mL of an identi- fi ed pathogen in the past 12 months. Uncomplicated UTI is de fi ned as an infection in a person with a normal urinary tract and function. 17 Women with complicated UTIs (ie, individuals with functional or structural abnor- malities  of  the  genitourinary  tract)  were  excluded. Within Europe, patients at fi rst diagnosis of RUTIs are offered an approach based on behavioural changes, anti- microbial prophylaxis or aspeci fi c non-antimicrobial pre- vention.  However,  several  women  refuse  to  take antimicrobials over an extended period of time; hence, intravesical administration of HA+CS is intended for women refractory or not satis fi ed with fi rst-line manage- ment of RUTIs. On the basis of a previous cohort study, 11 we estimated that 208 patients were needed to observe a 50% difference in the proportions of patients recurring between the two groups within 12 months with 90% power and an α -level of 0.05. Groups and interventions Patients were treated with intravesical administration of combined HA 1.6% and CS 2.0%. The recommended scheme is one instillation per week for the fi rst month, followed by one instillation every 2 weeks for the second month and one instillation per month afterwards until stable remission of the symptoms; however, different pat- terns are seen in clinical practice. These patients were compared  with  patients  treated  with  antimicrobial 2 Ciani O, etal . BMJOpen 2016; 6 :e009669. doi:10.1136/bmjopen-2015-009669 Open Access </p>
                                        
                                            <p>5. was  available  at  baseline  and  after  12 months  of follow-up. There was no evidence of better improvement in HRQoL in the HA+CS group compared with control with SF-36 results, whereas when EQ-5D data were con- sidered, the HA+CS group seemed to have received a higher bene fi t in terms of HRQoL than the control (see online supplementary table S1). There is a general reduction in physical units of health  resources  (ie,  medical  visits,  laboratory  and imaging tests) consumed by the two groups before the treatment and during the follow-up (see online supple- mentary  table  S2)  without  signi fi cant  differences between the two groups. Sensitivity analyses We repeated all primary analyses and considered differ- ent exposure intensity (ie, number of intravesical admin- istrations received) in the HA+CS group. All fi ndings consistently  show  the  additional  bene fi t  gained  by patients when the number of instillations increases, pos- sibly revealing the importance of adherence to this medical device therapy for the treatment of RUTIs ( table 4 ). As a post hoc subgroup analysis, we repeated primary analyses in non-sexually active patients only and obtained similar patterns of results as in the whole sample, although with loss of statistical signi fi cance. DISCUSSION In this European multicentre retrospective observational study, we compared bacteriologically con fi rmed recur- rence rates at the 12 month follow-up after the initiation of intravesical administration of HA+CS versus standard of care for the treatment of RUTIs. After adjusting for unbalanced  confounding  factors  between  the  two groups, we observed that the HA+CS patients had a 49% reduction (OR 0.51, 95% CI 0.27 to 0.96) in the risk of a bacteriologically con fi rmed recurrence, whereas there was no statistical evidence for a difference in the inci- dence and hazard rates of such recurrences between the two groups. Four clinical studies 28 – 31 have been performed to investigate the ef fi cacy and tolerability of intravesically administered GAG for RUTI prophylaxis, all showing that  HA  alone  or  HA+CS  instillations  reduce  the number of UTIs per patient per year at no increased risk of severe adverse events and prolong the time inter- val between RUTI episodes, with a high rate of patients being free of recurrence at the end of the study period. In particular, two randomised control trials (RCTs) studies  compared  HA+CS  administration  to  either placebo 29 or long-term antibiotic prophylaxis using sulfa- methoxazole  200 mg  and  trimethoprim  40 mg. 30 Damiano et  al report a decrease in the UTI rate per patient of 77% (95% CI 72.3 to 80.8) in the experimen- tal versus placebo group, whereas De Vita and collea- gues report the mean±SD number of recurrent cystitis per patient per year as 1±1.2 vs 2.3±1.4 in HA+CS and antibiotic treated patients, respectively. Despite the pro- spective  and  randomised  design,  these  trials  were limited by the small sample size (ie, they included 57 and 28 patients, respectively) and the single centre setting that considerably reduces the generalisability of Table 3 Incidence of bacteriologically confirmed recurrences during 12-month follow-up Incidence of bacteriologically confirmed recurrences (days) HA +CS (%) Standard care (%) p Value 0 – 90                   15.3    12.7        0.610 91 – 180                 15.6    12.9        0.628 181 – 240                10.7     3.7        0.132 241 – 365                16.3    30.8        0.043 HA+CS, hyaluronic acid and chondroitin sulfate. Table 4 Sensitivity analysis — impact of number of intravesical administration of HA+CS on clinical outcomes Bacteriologically confirmed recurrence                       OR (95% CI)              Adjusted* OR (95% CI) ≥ 5 Instillations (n=156) vs standard of care                      0.81 (0.48 to 1.36)         0.52 (0.27 to 0.99) ≥ 6 Instillations (n=134) vs standard of care                      0.69 (0.40 to 1.18)         0.47 (0.25 to 0.91) ≥ 7 Instillations (n=82) vs standard of care                       0.63 (0.34 to 1.14)         0.43 (0.21 to 0.88) Total number of bacteriologically confirmed recurrence          IRR (95% CI)             Adjusted* IRR (95% CI) ≥ 5 Instillations vs standard of care                             1.82 (1.33 to 2.49)         1.05 (0.73 to 1.52) ≥ 6 Instillations vs standard of care                             1.64 (1.18 to 2.28)         0.97 (0.66 to 1.40) ≥ 7 Instillations vs standard of care                             1.46 (1 to 2.13)            0.90 (0.60 to 1.36) Time to first bacteriologically confirmed recurrence              HR (95% CI)             Adjusted* HR (95% CI) ≥ 5 Instillations vs standard of care                             1.72 (1.12 to 2.65)         1.04 (0.64 to 1.71) ≥ 6 Instillations vs standard of care                             1.55 (0.99 to 2.41)         0.96 (0.58 to 1.57) ≥ 7 Instillations vs standard of care                             1.33 (0.79 to 2.22)         0.85 (0.49 to 1.47) *Adjusted for age, BMI, employment and menopause status, postcoital infections, dyspareunia, FSFI and severity of RUTI. BMI, body mass index; FSFI, Female Sexual Function Index; HA+CS, hyaluronic acid and chondroitin sulfate; IRR, incidence rate ratio; RUTI, recurrent urinary tract infection. Ciani O, etal . BMJOpen 2016; 6 :e009669. doi:10.1136/bmjopen-2015-009669 5 Open Access </p>
                                        
                                            <p>4. person-years, whereas in the standard treatment group there were 59 bacteriologically con fi rmed recurrences in 51.1 person-years (p=0.001). However, we observed an adjusted IRR (95% CI) of 0.99 (0.69 to 1.43), showing non-signi fi cant  differences  in  the  incidence  rates between the group treated with HA+CS and the control. Similar results were obtained from the univariate and multivariate Cox regression models used to estimate the HR (95% CI) for the time to fi rst bacteriologically con fi rmed recurrence, with an unadjusted estimate of 0.99 (0.61 to 1.61) ( table 2 ). Although the median time to fi rst recurrence was higher in the standard care group (169.5 days (IQR, 72.5 – 341.5) vs 320 days (IQR, 179 – 365);  p  value  &lt;0.001)  during  the  12-month follow-up, we observed the distribution of recurrences at separate follow-up times, and noted that the incident proportion of patients who developed the recurrence versus those still at risk was lower in the HA+CS group in the latest part of follow-up, after 8 months ( table 3 ). All patients were alive at the 12-month follow-up. There were 14 all-cause hospitalisations in the HA+CS group and 1 in the control group. HRQoL and resources consumption In a subset of patients, a measure of the HRQoL as mea- sured through the SF-36 or EQ-5D 3 level questionnaires Table 1 Baseline characteristics Characteristics                             HA+CS (N=181)            Standard care (N=95)          p Value Age — mean (SD)                            55.24 (17.33)              48.84 (21.16)                  0.017 Employed — n (%)                              83 (46)                   62 (65)                     0.003 Partner — n (%)                               148 (82)                   72 (76)                     0.172 Sexually active — n (%)                         114 (63)                   60 (63)                     0.931 Menopause — n (%)                            69 (28)                   49 (51)                     0.038 BMI — mean (SD)                            26.20 (6.37)               24.56 (5.03)                   0.019 Postcoital infections — n (%)                      31 (17)                   29 (31)                     0.012 Dyspareunia — n (%)                            40 (22)                    5 (5)                    &lt;0.001 Severity RUTI — median (IQR)*                     4 (2 – 5)                   4 (3 – 4)                    0.316 Prophylaxis — n (%) Antimicrobial prophylaxis continuous             NA                      42 (44.21) Antimicrobial prophylaxis postcoital              NA                      19 (20) Intermittent immunoactive prophylaxis            NA                      28 (29.47) On demand immunoactive therapy               NA                       1 (1.05) Others                                     NA                       5 (5.26) FSFI — mean (SD)                            5.35 (8.71)                3.13 (5.43)                   0.018 EQ-5D — median (IQR)                        0.69 (0.24 – 0.73) † 0.69 (0.28 – 0.81) ‡ 0.696 SF-36 PCS — median (IQR)                      60 (54.5 – 70)§              60 (53 – 67.5)¶               0.500 SF-36 MCS — median (IQR)                      60 (54 – 70)**               60 (53 – 67.5)¶               0.551 *According to the European Association of Urology Guidelines on Urological Infections where 1 is low severity cystitis and 6 is extreme severity including organ failure. 21 † N=90 patients. ‡ N=29 patients. §N=72 patients. ¶N=60 patients. **N=73 patients. BMI, body mass index; EQ-5D, Euro QoL 5D 3 level; FSFI, Female Sexual Function Index; HA+CS, hyaluronic acid and chondroitin sulfate; NA, not applicable; RUTI, recurrent urinary tract infection; SF-36 MCS, Short Form 36 mental component score; SF-36 PCS, Short Form 36 physical component score. Table 2 Bacteriologically confirmed recurrence, total number of recurrences and time to first recurrence between HA+CS versus standard of care treated patients Outcome                                              OR (95% CI)                Adjusted* OR (95% CI) Bacteriologically confirmed recurrence                        0.77 (0.46 to 1.28)            0.51 (0.27 to 0.96) IRR (95% CI)               Adjusted* IRR (95% CI) Total number of bacteriologically confirmed recurrence           1.73 (1.27 to 2.37)            0.99 (0.69 to 1.43) HR (95% CI)               Adjusted* HR (95% CI) Time to first bacteriologically confirmed recurrence              1.66 (1.09 to 2.54) † 0.99 (0.61 to 1.61) *Adjusted for age, BMI, employment and menopause status, postcoital infections, dyspareunia, FSFI and severity of RUTI. † Log-rank test p value 0.018. BMI, body mass index; FSFI, Female Sexual Function Index; HA+CS, hyaluronic acid and chondroitin sulfate; IRR, incidence rate ratio; RUTI, recurrent urinary tract infection. 4 Ciani O, etal . BMJOpen 2016; 6 :e009669. doi:10.1136/bmjopen-2015-009669 Open Access </p>
                                        
                                            <p>8. bacterial cystitis in adult women: a meta-analysis. Int Urogynecol J 2013;24:545 – 52. 22.  Madersbacher H, van Ophoven A, van Kerrebroeck PE. GAG layer replenishment therapy for chronic forms of cystitis with intravesical glycosaminoglycans — a review. Neurourol Urodyn 2013;32:9 – 18. 23.  Brazier JE, Harper R, Jones NM, et al . Validating the SF-36 health survey questionnaire: new outcome measure for primary care. BMJ 1992;305:160 – 4. 24.  EuroQol Group. EuroQol — a new facility for the measurement of health-related quality of life. Health Policy 1990;16:199 – 208. 25.  Lamers LM, McDonnell J, Stalmeier PF, et al . The Dutch tariff: results and arguments for an effective design for national EQ-5D valuation studies. Health Econ 2006;15:1121 – 32. 26.  Scalone L, Cortesi PA, Ciampichini R, et al . Italian population-based values of EQ-5D health states. Value Health 2013;16:814 – 22. 27.  Dolan P. Modeling valuations for EuroQol health states. Med Care 1997;35:1095 – 108. 28.  Constantinides C, Manousakas T, Nikolopoulos P, et al . Prevention of recurrent bacterial cystitis by intravesical administration of hyaluronic acid: a pilot study. BJU Int 2004;93:1262 – 6. 29.  Damiano R, Quarto G, Bava I, et al . Prevention of recurrent urinary tract infections by intravesical administration of hyaluronic acid and chondroitin sulphate: a placebo-controlled randomised trial. Eur Urol 2011;59:645 – 51. 30.  De Vita D, Giordano S. Effectiveness of intravesical hyaluronic acid/ chondroitin sulfate in recurrent bacterial cystitis: a randomized study. Int Urogynecol J 2012;23:1707 – 13. 31.  Lipovac M, Kurz C, Reithmayr F, et al . Prevention of recurrent bacterial urinary tract infections by intravesical instillation of hyaluronic acid. Int J Gynaecol Obstet 2007;96:192 – 5. 32.  Taur Y, Smith MA. Adherence to the Infectious Diseases Society of America guidelines in the treatment of uncomplicated urinary tract infection. Clin Infect Dis 2007;44:769 – 74. 33.  Little P, Merriman R, Turner S, et al . Presentation, pattern, and natural course of severe symptoms, and role of antibiotics and antibiotic resistance among patients presenting with suspected uncomplicated urinary tract infection in primary care: observational study. BMJ 2010;340:b5633. 34.  Ronald A. The etiology of urinary tract infection: traditional and emerging pathogens. Am J Med 2002;113(Suppl 1A):14S – 19S. 35.  Hooton TM, Levy SB. Antimicrobial resistance: a plan of action for community practice. Am Fam Physician 2001;63:1087 – 98. 36.  Fauci AS, Marston lD. The perpetual challenge of antimicrobial resistance. JAMA 2014;311:1853 – 4. 37.  Review on Antimicrobial Resistance. Antimicrobial resistance: tackling a crisis for the health and wealth of nations. 2014. http:// amr-review.org/sites/default/files/AMR%20Review%20Paper%20-% 20Tackling%20a%20crisis%20for%20the%20health%20and% 20wealth%20of%20nations_1.pdf 38.  [No authors listed]. Antimicrobial resistance: in terms politicians understand. Lancet 2014;384:2173. 39.  Woolhouse M, Farrar J. Policy: an intergovernmental panel on antimicrobial resistance. Nature 2014;509:555 – 7. 40.  Geoghegan-Quinn M. Funding for antimicrobial resistance research in Europe. Lancet 2014;384:1186. 8 Ciani O, etal . BMJOpen 2016; 6 :e009669. doi:10.1136/bmjopen-2015-009669 Open Access </p>
                                        
                                            <p>7. restrictive, if not naïve, cost-analysis as it is well known that all direct healthcare costs and consequences, includ- ing those for the wider society, as would be containment of  drug-resistance  spreading,  should  be  taken  into account when assessing the cost-effectiveness pro fi les of health technologies. Future methodologically sound eco- nomic evaluation studies are recommended to compare the societal or payer value of the two treatment strategies. CONCLUSIONS In order to treat and prevent RUTI, there is a need for effective and safe alternative strategies for antimicrobial therapy. Our study showed that in a real-world setting, bladder instillation of combined HA+CS may reduce the risk of bacteriologically con fi rmed recurrences com- pared with the current standard management in this study population. Total incidence rates and hazard rates were instead non-signi fi cantly different between the two groups. The number of HA+CS instillations seems to be an important marker of success for intravesical administra- tion therapy. Furthermore, in contrast to what happens with antibiotic prophylaxis, owing to side effects and devel- opment of resistance, the effectiveness of GAG reinstate- ment therapy improves over time, with an even better expected comparative effectiveness pro fi le in the long run. Although fi rm conclusions are dif fi cult due to the retrospective observational design, these fi ndings high- light the relevance of additional prospective and rando- mised studies in this area and the promising role of the HA+CS reinstatement therapy for prevention and treat- ment of RUTI in an era of worryingly increased AMR. Author affiliations 1 Centre for Research on Health and Social Care Management, Università Bocconi, Milan, Italy 2 Evidence Synthesis &amp; Modelling for Health Improvement, Institute of Health Research, University of Exeter Medical School, Exeter, UK 3 Diaconessenhuis, Maatschap, Urologie, Leiden, The Netherlands 4 Department of Urology, St. Cyril and Method University Hospital, Bratislava, Slovakia 5 Department of Urology, Fakultná nemocnica s poliklinikou, Pre š ov, Slovakia 6 Department of Surgical and Biomedical Science, University of Perugia, Urology and Andrology Clinic, Perugia, Italy 7 Department of Urology, University of Catania, Catania, Italy 8 Department of Urology, Jessenius School of Medicine, University Hospital, Martin, Slovakia 9 FNsP, Urologicka Klinika, Nové Zámky, Slovakia 10 Department of Urology, Humanitas Clinical and Research Center, Milan, Italy 11 Department of Policy Analysis and Public Management, Università Bocconi, Milano, Italy Twitter Follow Oriana Ciani at @OrianaCiani Contributors OC, RT and ML designed the study. EA, MR, RL, EC, MDB, GM, EF, TR, MB and GG contributed to the data collection. OC analysed the data and drafted the manuscript. All the authors commented on and approved the final version of the manuscript. Funding This study was funded by an unrestricted grant from the TETI Association — study group for urogenital diseases. Members of the association were involved in the data collection and revised the manuscript. Competing interests None declared. Ethics approval The study protocol was reviewed and approved at the coordinating centre by an Independent Ethics Committee at the Department of Urology, University of Perugia. Provenance and peer review Not commissioned; externally peer reviewed. Data sharing statement The data set is available by emailing the corresponding author. Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non- commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http:// creativecommons.org/licenses/by-nc/4.0/ REFERENCES 1.  Laupland KB, Ross T, Pitout JD, et al . Community-onset urinary tract infections: a population-based assessment. Infection 2007;35:150 – 3. 2.  Foxman B. Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. Am J Med 2002;113(Suppl 1A):5S – 13S. 3.  Foxman B, Barlow R, D ’ Arcy H, et al . Urinary tract infection: self-reported incidence and associated costs. Ann Epidemiol 2000;10:509 – 15. 4.  Hooton TM, Scholes D, Hughes JP, et al . A prospective study of risk factors for symptomatic urinary tract infection in young women. N Engl J Med 1996;335:468 – 74. 5.  Foxman B. The epidemiology of urinary tract infection. Nat Rev Urol 2010;7:653 – 60. 6.  Sen A. Recurrent cystitis in non-pregnant women. Clin Evid 2008;07:801. 7.  Ikaheimo R, Siitonen A, Heiskanen T, et al . Recurrence of urinary tract infection in a primary care setting: analysis of a 1-year follow-up of 179 women. Clin Infect Dis 1996;22:91 – 9. 8.  Foxman B. Recurring urinary tract infection: incidence and risk factors. Am J Public Health 1990;80:331 – 3. 9.  Foxman B, Gillespie B, Koopman J, et al . Risk factors for second urinary tract infection among college women. Am J Epidemiol 2000;151:1194 – 205. 10.  Albert X, Huertas I, Pereiró II, et al . Antibiotics for preventing recurrent urinary tract infection in non-pregnant women. Cochrane Database Syst Rev 2004;(3):CD001209. 11.  Ciani O, Grassi D, Tarricone R. An economic perspective on urinary tract infection: the ‘ costs of resignation ’ . Clin Drug Investig 2013;33:255 – 61. 12.  Renard J, Ballarini S, Mascarenhas T, et al . Recurrent lower urinary tract infections have a detrimental effect on patient quality of life: a prospective, observational study. Infect Dis Ther 2015;4:125 – 35. 13.  Bermingham SL, Ashe JF. Systematic review of the impact of urinary tract infections on health-related quality of life. BJU Int 2012;110(Pt C):E830 – 6. 14.  Gupta K, Trautner BW. Diagnosis and management of recurrent urinary tract infections in non-pregnant women. BMJ 2013;346:f3140. 15.  Arya LA, Northington GM, Asfaw T, et al . Evidence of bladder oversensitivity in the absence of an infection in premenopausal women with a history of recurrent urinary tract infections. BJU Int 2012;110:247 – 51. 16.  Gupta K, Hooton TM, Naber KG, et al . International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis 2011;52:e103 – 20. 17.  Grabe M, Bartoletti R, Bjerklund Johansen T, et al . Guidelines on urological infections. Eur Assoc Urol 2015. http://uroweb.org/wp- content/uploads/19-Urological-infections_LR2.pdf 18.  Shepherd AK, Pottinger PS. Management of urinary tract infections in the era of increasing antimicrobial resistance. Med Clin North Am 2013;97:737 – 57, xii. 19.  Schito GC, Naber KG, Botto H, et al . The ARESC study: an international survey on the antimicrobial resistance of pathogens involved in uncomplicated urinary tract infections. Int J Antimicrob Agents 2009;34:407 – 13. 20.  Lazzeri M, Montorsi F. The therapeutic challenge of “ chronic cystitis ” : search well, work together, and gain results. Eur Urol 2011;60:78 – 80. 21.  De Vita D, Antell H, Giordano S. Effectiveness of intravesical hyaluronic acid with or without chondroitin sulfate for recurrent Ciani O, etal . BMJOpen 2016; 6 :e009669. doi:10.1136/bmjopen-2015-009669 7 Open Access </p>
                                        
                                            <p></p>
                                        
                                    
                                </div>
                                <div role="tabpanel" class="tab-pane fade" id="statistic" slide-url="intravesical-administration-of-combined-hyaluronic-acid-ha-and-chondroitin-sulfate-cs-for-the-treatment-of-female-recurrent-urinary-tract-infections-2016-bmjopen-2015-009669-30.html">
                                    <div class="row">
                                        <div class="col-lg-4">
                                            <h4 class="mt0 oe_slides_statistics_title">Nézetek</h4>
                                            <ul class="list-group">
                                                <li class="list-group-item">
                                                    <span class="badge badge-pill">1220</span>
                                                    <i class="fa fa-play"></i> Total Views
                                                </li>
                                                <li class="list-group-item">
                                                    <span class="badge badge-pill">917</span>
                                                    <i class="fa fa-circle-o"></i> Website Views
                                                </li>
                                                <li class="list-group-item">
                                                    <span class="badge badge-pill">303</span>
                                                    <i class="fa fa-code"></i> Embedded Views
                                                </li>
                                            </ul>
                                        </div>

                                        <div class="col-lg-4">
                                            <h4 class="mt0 oe_slides_statistics_title">Műveletek</h4>
                                            <ul class="list-group">
                                                <li class="list-group-item">
                                                    <span class="badge badge-pill" id="total-share">0</span>
                                                    <i class="fa fa-share-alt"></i> Social Shares
                                                </li>
                                                <li class="list-group-item">
                                                    <span class="badge badge-pill">0</span>
                                                    <i class="fa fa-thumbs-up"></i> Likes
                                                </li>
                                                <li class="list-group-item">
                                                    <span class="badge badge-pill">0</span>
                                                    <i class="fa fa-thumbs-down"></i> Nemkedvelések
                                                </li>
                                                <li class="list-group-item">
                                                    <span class="badge badge-pill">0</span>
                                                    <i class="fa fa-comments-o"></i> Comments
                                                </li>
                                            </ul>
                                        </div>

                                        <div class="col-lg-4">
                                            <h4 class="mt0 oe_slides_statistics_title">Share count</h4>
                                            <ul class="list-group">
                                                <li class="list-group-item">
                                                    <span class="badge badge-pill" id="facebook-badge">0</span>
                                                    <i class="fa fa-facebook-square"></i> Facebook
                                                </li>
                                                <li class="list-group-item">
                                                    <span class="badge badge-pill" id="twitter-badge">0</span>
                                                    <i class="fa fa-twitter-square"></i> Twitter
                                                </li>
                                                <li class="list-group-item">
                                                    <span class="badge badge-pill" id="linkedin-badge">0</span>
                                                    <i class="fa fa-linkedin-square"></i> LinkedIn
                                                </li>
                                                <li class="list-group-item">
                                                    <span class="badge badge-pill" id="google-badge">0</span>
                                                    <i class="fa fa-google-plus-square"></i> Google+
                                                </li>
                                            </ul>
                                        </div>
                                    </div>
                                    <div class="row">
                                        <div class="col-lg-12">
                                            <h4 class="mt0"> Embeds
                                                <span class="badge badge-pill float-right">
                                                    3
                                                </span>
                                            </h4>
                                            <ul class="list-group" style="height: 150px;overflow: auto;">
                                                <li class="list-group-item">
                                                    <span class="badge badge-pill">13</span>
                                                    hbs.hu
                                                </li><li class="list-group-item">
                                                    <span class="badge badge-pill">4</span>
                                                    www.hbs.hu
                                                </li><li class="list-group-item">
                                                    <span class="badge badge-pill">2</span>
                                                    odoo.hbs.hu
                                                </li>
                                            </ul>
                                        </div>
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
                <div class="col-xl-4 col-lg-4 col-md-12 col-12">
                    <ul class="nav nav-tabs" role="tablist">
                        <li class="nav-item"><a aria-controls="related" href="#related" class="nav-link active" data-toggle="tab">Kapcsolódó</a></li>
                        <li class="nav-item"><a aria-controls="most_viewed" href="#most_viewed" class="nav-link" data-toggle="tab">Most Viewed</a></li>
                    </ul>
                    <div class="tab-content">
                        <div role="tabpanel" id="related" class="tab-pane active mt4">
                            <div class="card">
                                <ul class="list-unstyled card-body">
                                    
                                    
                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="cuaj-5-6-e136-17.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/17/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="cuaj-5-6-e136-17.html"><h6 class="mb-1">cuaj-5-6-e136</h6></a>
            <small class="text-muted">
                1558 Views . <timeago class="timeago" datetime="2019-10-31 13:27:48.254982"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="minimally-invasive-device-for-intravesical-instillation-lovasz-2019-international-journal-of-urology-18.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/18/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="minimally-invasive-device-for-intravesical-instillation-lovasz-2019-international-journal-of-urology-18.html"><h6 class="mb-1">Minimally invasive device for intravesical instillation-Lovasz-2019-International_Journal_of_Urology</h6></a>
            <small class="text-muted">
                1503 Views . <timeago class="timeago" datetime="2019-10-31 13:28:10.125299"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="cikk-a-neurourology-and-urodynamics-ban-2018-19.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/19/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="cikk-a-neurourology-and-urodynamics-ban-2018-19.html"><h6 class="mb-1">Cikk a Neurourology and Urodynamics-ban 2018.</h6></a>
            <small class="text-muted">
                1472 Views . <timeago class="timeago" datetime="2019-10-31 13:28:23.618732"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="ic-bps-treatment-checklist-20.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/20/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="ic-bps-treatment-checklist-20.html"><h6 class="mb-1">IC-BPS Treatment Checklist</h6></a>
            <small class="text-muted">
                1497 Views . <timeago class="timeago" datetime="2019-10-31 13:28:50.163748"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="ic-bps-diagnostic-algorhytm-21.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/21/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="ic-bps-diagnostic-algorhytm-21.html"><h6 class="mb-1">IC-BPS diagnostic algorhytm.</h6></a>
            <small class="text-muted">
                1487 Views . <timeago class="timeago" datetime="2019-10-31 13:29:57.450898"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="glycosaminoglycan-therapy-for-bladder-diseases-22.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/22/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="glycosaminoglycan-therapy-for-bladder-diseases-22.html"><h6 class="mb-1">Glycosaminoglycan Therapy for Bladder Diseases</h6></a>
            <small class="text-muted">
                1384 Views . <timeago class="timeago" datetime="2019-10-31 13:30:10.980936"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="essic-2017-budapest-abstracts-23.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/23/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="essic-2017-budapest-abstracts-23.html"><h6 class="mb-1">ESSIC 2017 Budapest abstracts</h6></a>
            <small class="text-muted">
                1463 Views . <timeago class="timeago" datetime="2019-10-31 13:30:38.129948"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="prevalence-of-symptoms-of-bladder-pain-syndrome-2011-24.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/24/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="prevalence-of-symptoms-of-bladder-pain-syndrome-2011-24.html"><h6 class="mb-1">Prevalence of Symptoms of Bladder Pain Syndrome 2011</h6></a>
            <small class="text-muted">
                1303 Views . <timeago class="timeago" datetime="2019-10-31 13:30:57.131521"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="the-urinary-microbiota-of-men-and-women-and-its-changes-in-women-during-bacterial-vaginosis-and-antibiotic-treatment-2017-25.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/25/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="the-urinary-microbiota-of-men-and-women-and-its-changes-in-women-during-bacterial-vaginosis-and-antibiotic-treatment-2017-25.html"><h6 class="mb-1">The urinary microbiota of men and women and its changes in women during bacterial vaginosis and antibiotic treatment. 2017</h6></a>
            <small class="text-muted">
                1361 Views . <timeago class="timeago" datetime="2019-10-31 13:35:55.689470"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="interstitial-cystitis-associated-urinary-metabolites-identified-by-mass-spectrometry-based-metabolomics-analysis-2016-26.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/26/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="interstitial-cystitis-associated-urinary-metabolites-identified-by-mass-spectrometry-based-metabolomics-analysis-2016-26.html"><h6 class="mb-1">Interstitial Cystitis-Associated Urinary Metabolites Identified by Mass-Spectrometry Based Metabolomics Analysis. 2016</h6></a>
            <small class="text-muted">
                1298 Views . <timeago class="timeago" datetime="2019-10-31 13:36:14.959707"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="pentosan-polysulfate-sodium-for-therapy-of-ic-urology-1990-27.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/27/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="pentosan-polysulfate-sodium-for-therapy-of-ic-urology-1990-27.html"><h6 class="mb-1">PENTOSAN POLYSULFATE SODIUM FOR THERAPY of IC Urology 1990</h6></a>
            <small class="text-muted">
                1413 Views . <timeago class="timeago" datetime="2019-10-31 13:37:27.415502"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="interstitial-cystitis-intravesical-therapy-tau-06-s2-s171-2017-28.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/28/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="interstitial-cystitis-intravesical-therapy-tau-06-s2-s171-2017-28.html"><h6 class="mb-1">Interstitial cystitis intravesical therapy tau-06-S2-S171 2017</h6></a>
            <small class="text-muted">
                1367 Views . <timeago class="timeago" datetime="2019-10-31 13:38:04.204366"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="novel-targeted-bladder-drug-delivery-systems-rru-7-169-2015-29.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/29/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="novel-targeted-bladder-drug-delivery-systems-rru-7-169-2015-29.html"><h6 class="mb-1">Novel targeted bladder drug-delivery systems rru-7-169 2015</h6></a>
            <small class="text-muted">
                1488 Views . <timeago class="timeago" datetime="2019-10-31 13:38:18.425299"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="intravesical-treatment-with-highly-concentrated-hyaluronic-acid-and-chondroitin-sulphate-in-patients-with-recurrent-urinary-tract-infections-results-from-a-multicentre-survey-cuaj-9-10-e721-31.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/31/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="intravesical-treatment-with-highly-concentrated-hyaluronic-acid-and-chondroitin-sulphate-in-patients-with-recurrent-urinary-tract-infections-results-from-a-multicentre-survey-cuaj-9-10-e721-31.html"><h6 class="mb-1">Intravesical treatment with highly-concentrated hyaluronic acid and chondroitin sulphate in patients with recurrent urinary tract infections- Results from a multicentre survey.cuaj-9-10-e721</h6></a>
            <small class="text-muted">
                1386 Views . <timeago class="timeago" datetime="2019-10-31 13:39:08.628954"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="ic-bps-and-glycosaminoglycans-replacement-therapy-2015-tau-04-06-638-32.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/32/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="ic-bps-and-glycosaminoglycans-replacement-therapy-2015-tau-04-06-638-32.html"><h6 class="mb-1">IC_BPS and glycosaminoglycans replacement therapy 2015 tau-04-06-638</h6></a>
            <small class="text-muted">
                1249 Views . <timeago class="timeago" datetime="2019-10-31 13:39:22.993300"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="managing-chronic-bladder-diseases-with-the-administration-of-exogenous-glycosaminoglycans-an-update-on-the-evidence-2016-urology-33.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/33/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="managing-chronic-bladder-diseases-with-the-administration-of-exogenous-glycosaminoglycans-an-update-on-the-evidence-2016-urology-33.html"><h6 class="mb-1">Managing chronic bladder diseases with the administration of exogenous glycosaminoglycans- an update on the evidence 2016 Urology</h6></a>
            <small class="text-muted">
                1387 Views . <timeago class="timeago" datetime="2019-10-31 13:40:52.836690"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="hyaluronic-acid-and-its-composites-as-a-local-antimicrobial-antiadhesive-barrier-2017-jbjiv02p0063-34.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/34/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="hyaluronic-acid-and-its-composites-as-a-local-antimicrobial-antiadhesive-barrier-2017-jbjiv02p0063-34.html"><h6 class="mb-1">Hyaluronic Acid and Its Composites as a Local Antimicrobial-Antiadhesive Barrier 2017.jbjiv02p0063</h6></a>
            <small class="text-muted">
                1309 Views . <timeago class="timeago" datetime="2019-10-31 13:45:41.648470"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="evidence-based-criteria-for-the-pain-of-ic-bps-in-women-2008-nihms43157-35.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/35/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="evidence-based-criteria-for-the-pain-of-ic-bps-in-women-2008-nihms43157-35.html"><h6 class="mb-1">Evidence-based criteria for the pain of IC_BPS in women 2008 nihms43157</h6></a>
            <small class="text-muted">
                1299 Views . <timeago class="timeago" datetime="2019-10-31 13:45:59.326213"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="intravesical-glycosaminoglycan-replacement-with-chondroitin-2015-article-306-36.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/36/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="intravesical-glycosaminoglycan-replacement-with-chondroitin-2015-article-306-36.html"><h6 class="mb-1">Intravesical Glycosaminoglycan Replacement with Chondroitin_2015_Article_306</h6></a>
            <small class="text-muted">
                1357 Views . <timeago class="timeago" datetime="2019-10-31 13:46:19.773972"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="intravesical-administration-of-combined-hyaluronic-acid-ha-and-chondroitin-sulphate-cs-for-the-treatment-of-female-recurrent-urinary-tract-infections-bmjopen-2015-009669-37.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/37/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="intravesical-administration-of-combined-hyaluronic-acid-ha-and-chondroitin-sulphate-cs-for-the-treatment-of-female-recurrent-urinary-tract-infections-bmjopen-2015-009669-37.html"><h6 class="mb-1">Intravesical administration of combined hyaluronic acid (HA) and chondroitin sulphate (CS) for the treatment of female recurrent urinary tract infections- bmjopen-2015-009669</h6></a>
            <small class="text-muted">
                1239 Views . <timeago class="timeago" datetime="2019-10-31 13:46:36.042595"></timeago>
            </small>
        </div>
    </li>

                                    
                                </ul>
                            </div>
                        </div>
                        <div role="tabpanel" id="most_viewed" class="tab-pane  mt4">
                            <div class="card">
                                <ul class="list-unstyled card-body">
                                    
                                    
                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="sugarvedo-ruhazat-ismerteto-3.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/3/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="sugarvedo-ruhazat-ismerteto-3.html"><h6 class="mb-1">Sugárvédő ruházat ismertető</h6></a>
            <small class="text-muted">
                3284 Views . <timeago class="timeago" datetime="2018-10-20 14:31:25.547995"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="op-set-system-5.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/5/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="op-set-system-5.html"><h6 class="mb-1">OP Set System</h6></a>
            <small class="text-muted">
                3044 Views . <timeago class="timeago" datetime="2018-11-16 13:38:03.543744"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="kompresszios-polya-felhelyezese-8.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/8/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="kompresszios-polya-felhelyezese-8.html"><h6 class="mb-1">Kompressziós pólya felhelyezése</h6></a>
            <small class="text-muted">
                2846 Views . <timeago class="timeago" datetime="2018-11-16 13:39:25.884480"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="kotszer-polya-l-r-6.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/6/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="kotszer-polya-l-r-6.html"><h6 class="mb-1">Kötszer Pólya L&amp;R</h6></a>
            <small class="text-muted">
                2643 Views . <timeago class="timeago" datetime="2018-11-16 13:38:35.611223"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="nedves-sebkezeles-flyer-l-r-7.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/7/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="nedves-sebkezeles-flyer-l-r-7.html"><h6 class="mb-1">Nedves sebkezelés flyer L&amp;R</h6></a>
            <small class="text-muted">
                2438 Views . <timeago class="timeago" datetime="2018-11-16 13:38:59.835920"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="pdb-actico-ulcersys-liner-10.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/10/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="pdb-actico-ulcersys-liner-10.html"><h6 class="mb-1">PDB_Actico UlcerSys Liner</h6></a>
            <small class="text-muted">
                2324 Views . <timeago class="timeago" datetime="2018-11-16 13:39:54.728282"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="scican-statim-g4-2.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/2/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="scican-statim-g4-2.html"><h6 class="mb-1">SciCan STATIM G4</h6></a>
            <small class="text-muted">
                2321 Views . <timeago class="timeago" datetime="2018-10-20 14:10:02.671163"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="pdb-actico-ulcersys-9.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/9/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="pdb-actico-ulcersys-9.html"><h6 class="mb-1">PDB_Actico UlcerSys</h6></a>
            <small class="text-muted">
                2209 Views . <timeago class="timeago" datetime="2018-11-16 13:39:42.488113"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="urostill-hasznalati-utmutato-v1-1-12.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/12/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="urostill-hasznalati-utmutato-v1-1-12.html"><h6 class="mb-1">UroStill_hasznalati_utmutato_v1.1</h6></a>
            <small class="text-muted">
                2038 Views . <timeago class="timeago" datetime="2019-10-31 13:22:24.531510"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="koronavirus-jarvany-61.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/61/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="koronavirus-jarvany-61.html"><h6 class="mb-1">KORONAVIRUS JARVANY</h6></a>
            <small class="text-muted">
                1773 Views . <timeago class="timeago" datetime="2020-04-09 15:16:22.317496"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="scican-statim-g4-1.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/1/image_thumb.jpg"/>
        </a>
        <div class="media-body">
            <a href="scican-statim-g4-1.html"><h6 class="mb-1">SciCan Statim G4</h6></a>
            <small class="text-muted">
                1708 Views . <timeago class="timeago" datetime="2018-10-20 14:09:31.661802"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="new-aiding-device-for-self-instillation-v2-16.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/16/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="new-aiding-device-for-self-instillation-v2-16.html"><h6 class="mb-1">New_aiding_device_for_self-instillation_v2</h6></a>
            <small class="text-muted">
                1690 Views . <timeago class="timeago" datetime="2019-10-31 13:23:48.863175"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="kitpack-11.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/11/image_thumb.jpg"/>
        </a>
        <div class="media-body">
            <a href="kitpack-11.html"><h6 class="mb-1">Kitpack</h6></a>
            <small class="text-muted">
                1684 Views . <timeago class="timeago" datetime="2018-11-16 14:52:39.736537"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="icbps-szoszedet-14.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/14/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="icbps-szoszedet-14.html"><h6 class="mb-1">ICBPS_SZÓSZEDET</h6></a>
            <small class="text-muted">
                1618 Views . <timeago class="timeago" datetime="2019-10-31 13:23:06.826135"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="ic-faq-s-and-appropriate-answers-mumbai-2019-15.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/15/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="ic-faq-s-and-appropriate-answers-mumbai-2019-15.html"><h6 class="mb-1">IC - FAQ-s and appropriate answers Mumbai 2019</h6></a>
            <small class="text-muted">
                1612 Views . <timeago class="timeago" datetime="2019-10-31 13:23:19.219912"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="urostill-users-manual-v1-1-13.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/13/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="urostill-users-manual-v1-1-13.html"><h6 class="mb-1">UroStill_Users_Manual_v1.1</h6></a>
            <small class="text-muted">
                1605 Views . <timeago class="timeago" datetime="2019-10-31 13:22:47.677753"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="l-r-corporate-film-4.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/4/image_thumb.jpg"/>
        </a>
        <div class="media-body">
            <a href="l-r-corporate-film-4.html"><h6 class="mb-1">L&amp;R Corporate Film</h6></a>
            <small class="text-muted">
                1601 Views . <timeago class="timeago" datetime="2018-11-14 15:53:51.760680"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="cuaj-5-6-e136-17.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/17/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="cuaj-5-6-e136-17.html"><h6 class="mb-1">cuaj-5-6-e136</h6></a>
            <small class="text-muted">
                1558 Views . <timeago class="timeago" datetime="2019-10-31 13:27:48.254982"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="minimally-invasive-device-for-intravesical-instillation-lovasz-2019-international-journal-of-urology-18.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/18/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="minimally-invasive-device-for-intravesical-instillation-lovasz-2019-international-journal-of-urology-18.html"><h6 class="mb-1">Minimally invasive device for intravesical instillation-Lovasz-2019-International_Journal_of_Urology</h6></a>
            <small class="text-muted">
                1503 Views . <timeago class="timeago" datetime="2019-10-31 13:28:10.125299"></timeago>
            </small>
        </div>
    </li>

                                    
                                        
    <li class="media mt-3">
        <a class="mr-3" href="ic-bps-treatment-checklist-20.html">
            <img class="oe_slides_apart_small" alt="slide.name" src="../../web/image/slide.slide/20/image_thumb.png"/>
        </a>
        <div class="media-body">
            <a href="ic-bps-treatment-checklist-20.html"><h6 class="mb-1">IC-BPS Treatment Checklist</h6></a>
            <small class="text-muted">
                1497 Views . <timeago class="timeago" datetime="2019-10-31 13:28:50.163748"></timeago>
            </small>
        </div>
    </li>

                                    
                                </ul>
                            </div>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    
                </main>
                <footer class="bg-light o_footer">
                    <div id="footer" class="oe_structure oe_structure_solo">
      <section class="s_text_block pb8 pt40">
        <div class="container">
          <div class="row" style="border-top: solid 1px #ddd; padding-top: 30px;">
            <div class="col-lg-4">
              <h5>További tartalmak</h5>
              <ul class="list-unstyled">
                <li>
                  <a href="../../blog/hirek-esemenyek-1.html" data-original-title="" title="" aria-describedby="tooltip310735">Blog</a>
                  <br/>
                  <a href="../../adatkezelesi-tajekoztato.html">Adatkezelési tájékoztató</a>
                </li>
                <li>
                  <br/>
                </li>
              </ul>
            </div>
            <div class="col-lg-4" id="connect">
              <h5>Elérhetőségek</h5>
              <ul class="list-unstyled">
                <li>
                  <i class="fa fa-phone"></i>
                  <span data-note-id="2">+36 1 452 1700</span>
                </li>
                <li>
                  <i class="fa fa-envelope"></i>
                  <span><a href="../../cdn-cgi/l/email-protection.html" class="__cf_email__" data-cfemail="c7aea9a1a887afa5b4e9afb2">[email&#160;protected]</a></span>
                </li>
              </ul>
              <p> </p>
            </div>
            <div class="col-lg-4">
              <h5>
                <span>HBS Medical</span>
                <small> – <a href="../../aboutus.html" data-original-title="" title="" aria-describedby="tooltip425138">Kapcsolat</a></small>
              </h5>
              <p>&nbsp;<br/></p>
            </div>
          </div>
        </div>
      </section>
    </div>
  <div class="o_footer_copyright">
            <div class="container">
                <div class="row">
                    <div class="col-lg-6 text-muted text-center text-md-left">
                        <span>Copyright &copy;</span> <span itemprop="name">HBS Medical</span>
                        
    

                    </div>
                    <div class="col-lg-6 text-right o_not_editable">
                        
    <div class="o_brand_promotion text-muted">
        Az oldalt készítette:
        <a href="https://eyssen.hu/" target="_blank"><img src="../../web/image/606/eyssen_logo_blue.png" width="120"/></a>
    </div>

                    </div>
                </div>
            </div>
        </div>
    </footer>
            </div>
        <script data-cfasync="false" src="../../cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script id="tracking_code">
            (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
            (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
            m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
            })(window,document,'script','https://www.google-analytics.com/analytics.js','ga');

            ga('create', _.str.trim('UA-52898474-1'), 'auto');
            ga('send','pageview');
        </script>
    
        
            </body>
        
<!-- Mirrored from hbs.hu/slides/slide/intravesical-administration-of-combined-hyaluronic-acid-ha-and-chondroitin-sulfate-cs-for-the-treatment-of-female-recurrent-urinary-tract-infections-2016-bmjopen-2015-009669-30 by HTTrack Website Copier/3.x [XR&CO'2014], Mon, 31 May 2021 16:04:10 GMT -->
</html>
    
    
